PacBio Nears Settlement of 'At Least' $7.7M over Litigation Related to its 2010 IPO | GenomeWeb

NEW YORK (GenomeWeb News) – Pacific Biosciences is closing in on a settlement over a class action lawsuit related to its initial public offering, the company has confirmed to GenomeWeb Daily News.

On October 25, a hearing will be held in Superior Court of California, County of San Mateo before Judge Marie Weiner to determine whether a settlement between PacBio and plaintiffs will be approved. The amount of the settlement is for "at least" approximately $7.7 million, the plaintiffs' lawyers said in a notice about the court hearing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Feb
25
Sponsored by
Omicia

This webinar will demonstrate how ACMG's recommended variant scoring and classification rules may be applied to standardize reporting on sequencing test results within and across institutions. 

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies. 

Mar
17
Sponsored by
Qiagen

This webinar will discuss Qiagen's approach to address two challenges facing NGS in the clinical research setting: lack of seamless workflow for routine clinical research use and truly relevant content to guide clinical research activities.